ASH: CBIO Awaiting Next Catalyst, BLUE In The Pink, STML Keeps Growing

(RTTNews) - The 59th American Society of Hematology (ASH) Annual Meeting is just around the corner. More than 250 pharmaceutical companies will be participating in the meeting which will be held between December 9 and December 12, 2017, at Atlanta, Georgia.

Listed below are some of the companies, which will be presenting new data or updated analyses from their hematology clinical trials.

Catalyst Biosciences Inc. (CBIO), which is well below its 52-week high of $21.30, has gained over 113% in the last 3 months.

At the American Hematological Society Conference on December 9, 2017, the Company will be presenting interim results from its phase 1/2 proof-of-concept clinical trial of subcutaneous Factor IX CB 2679d in individuals with severe hemophilia B. Complete results from this study are expected in early 2018.

The Company has a strategic collaboration with South Korean biologics manufacturing and development company Isu Abxis for the development of CB 2679d.

CBIO closed Friday's (Dec.1) trading at $7.10, up 1.57%.

Stemline Therapeutics Inc. (STML), which touched a new 52-week high of $15.60 on Friday, has returned an impressive 99% over the last 6 months.

The Company will be presenting updated clinical data from its pivotal phase II trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) on December 9, 2017. This, pivotal phase II trial of SL-401 in BPDCN, the results of which were reported in October of this year, has met the primary endpoint.

To know more about STML, please visit our Company Spotlight column.

STML, which touched a new 52-week high of $15.60 on Friday, closed the day's trading at $7.10, up 1.57%.

bluebird bio Inc. (BLUE) has returned an impressive 177% year-to-date, thanks to the continued progress in its clinical development goals.

LentiGlobin in development for patients with transfusion-dependent ß-thalassemia (TDT) and severe sickle cell disease (SCD), and bb2121 and bb21217 for patients with relapsed/refractory multiple myeloma are the Company's investigational drugs.

LentiGlobin is under a phase III study in patients with transfusion-dependent ß-thalassemia (TDT) with the ß0/ß0 genotype, dubbed Northstar-3; a phase III study in patients with TDT and non-ß0/ß0 genotypes, known as Northstar-2; a phase I/II study in patients with TDT and all genotypes, dubbed Northstar; a phase I study in patients with TDT and severe sickle cell disease, dubbed HGB-205, and a phase I study in patients with sickle cell disease, known as HGB-206.

bb2121 and bb21217, co-developed by Celgene, are under phase I trials for the treatment of relapsed/refractory multiple myeloma.

New data from clinical studies of LentiGlobin and bb2121 will be presented at the ASH Annual Meeting on December 9th, 10th and 11th.

BLUE touched a new 52-week intraday high of $174.65 on Friday, before closing the day's trading at $171.10, down 0.98%.

It's been a banner year for GlycoMimetics Inc. (GLYC), whose share price has risen as much as 172% year-to-date.

The Company's lead product candidate is Rivipansel for the treatment of vaso-occlusive crisis of sickle cell disease, which is under phase III testing. Rivipansel is licensed to Pfizer by GlycoMimetics under an agreement signed between the two companies in 2011. This study is on track for completion in the second half of 2018.

A phase 1/2 trial of GMI-1271 in acute myeloid leukemia (AML) and a phase I trial of GMI-1359, a potential treatment for hematologic malignancies, in healthy volunteers are the other two clinical programs of the Company.

On May 18, 2017, the Company announced promising data from the phase 1/2 trial of GMI-1271 in AML, which demonstrated high overall response rates, low mortality rates and promising initial survival outcomes. The news sent the stock soaring 115% that day.

On December 11, 2017, at the ASH meeting, the Company will be reporting additional data from the phase 1/2 trial of GMI-1271 in acute myeloid leukemia. The new data will focus on survival and duration of response in two patient populations, namely relapsed/refractory AML patients, and newly diagnosed AML patients, aged 60 and older.

GLYC closed Friday's trading at $14.08, down 0.21%.